Karyopharm Therapeutics Inc.

Newton,  MA 
United States
https://www.karyopharm.com/pipeline/

• Booth: 2074a

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.

Brands: https://events.jspargo.com/ASCO21/CUSTOM/KPTI-logo_Blue-duotone_1140x250.jpg

 Show Specials

• View our Mechanism of Action (Apr 21, 2021)
  https://vimeo.com/512984196/fb26771b28

 Press Releases

• 5. Learn About the Role of XPO1 (Apr 21, 2021)

  https://app-staging.healthcasts.com/prg-asset/karyopharm-mod-index

• 3. Product Website (Apr 21, 2021)
  https://www.xpoviopro.com/

• 1. Product Information Fact Sheet (Apr 21, 2021)
  https://www.xpoviopro.com/assets/pdf/mm/XPOVIO_Fact_Sheet.pdf 

• 2. Prescribing Information (Apr 21, 2021)
  https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf

• 4. Patient Profiles (Apr 21, 2021)
  https://www.xpoviopro.com/content/pdf/mm/MM-BOSTON-Patient-Profiles.pdf

 Products